Ali, H. , Ghaysaa, H. , Jaafar, W. and Malek, M. (2025) Ischemic Stroke Following Coronary Angiography: A Case Report. Case Reports in Clinical Medicine, 14, 123-129. doi: 10.4236/crcm.2025.143016 .
The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.
The study, published March 12 in JAMA Network Open, compared the newly approved tenecteplase in a single quick injection to alteplase, the stroke treatment that has been used for decades and requires ...
Medical Device Network on MSN1d
FDA clears Perfuze’s Zipline access catheter for stroke treatmentCoinciding with the FDA’s clearance for the catheter, Perfuze has also completed a €22m ($24m) financing round.
Perfuze, an Ireland-based developer of catheter-based aspiration technology for the treatment of acute ischemic stroke, ...
A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a ...
The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.
The following is a summary of “Reducing time delays and enhancing reperfusion eligibility related to stroke suspicion by the ...
For patients with acute ischemic stroke whose symptoms began 4.5 to 24 hours earlier, alteplase is associated with a higher percentage of patients achieving a score of 0 or 1 on the modified Rankin ...
TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
Health and Me on MSN8d
FDA Approves TNKase To Treat Ischemic Strokes In AdultsIt is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback